These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7880928)

  • 1. Chronic myelogenous leukemia and exposure to ionizing radiation--a retrospective study of 443 patients.
    Corso A; Lazzarino M; Morra E; Merante S; Astori C; Bernasconi P; Boni M; Bernasconi C
    Ann Hematol; 1995 Feb; 70(2):79-82. PubMed ID: 7880928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myelogenous leukemia following repeated radiation therapy for histiocytosis X.
    Chap L; Nimer SD
    Leuk Lymphoma; 1994 Jan; 12(3-4):315-6. PubMed ID: 8167563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of chronic myeloid leukemia: can the dose-response curve be U-shaped?
    Radivoyevitch T; Kozubek S; Sachs RK
    Radiat Res; 2002 Jan; 157(1):106-9. PubMed ID: 11754648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal.
    Aguiar RC
    Leuk Lymphoma; 1998 Mar; 29(1-2):17-26. PubMed ID: 9638972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results.
    Cortes JE; Talpaz M; Beran M; O'Brien SM; Rios MB; Stass S; Kantarjian HM
    Cancer; 1995 Jan; 75(2):464-70. PubMed ID: 7812917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR rearrangement-negative chronic myelogenous leukemia revisited.
    Kurzrock R; Bueso-Ramos CE; Kantarjian H; Freireich E; Tucker SL; Siciliano M; Pilat S; Talpaz M
    J Clin Oncol; 2001 Jun; 19(11):2915-26. PubMed ID: 11387365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study.
    Lee JP; Birnstein E; Masiello D; Yang D; Yang AS
    J Hematol Oncol; 2009 Jul; 2():30. PubMed ID: 19630970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Radiation-related CML].
    Kamada N
    Nihon Rinsho; 2001 Dec; 59(12):2329-35. PubMed ID: 11766334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The allometry of chronic myeloid leukemia.
    Pacheco JM; Traulsen A; Dingli D
    J Theor Biol; 2009 Aug; 259(3):635-40. PubMed ID: 19362566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
    Ko PS; Yu YB; Liu YC; Wu YT; Hung MH; Gau JP; Liu CJ; Hsiao LT; Chen PM; Chiou TJ; Liu CY; Liu JH
    Curr Med Res Opin; 2017 Oct; 33(10):1737-1744. PubMed ID: 28715941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
    Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
    Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
    Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
    Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
    Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk and impact of tuberculosis in patients with chronic myeloid leukemia: a nationwide population-based study in Taiwan.
    Liu CJ; Hong YC; Teng CJ; Hung MH; Hu YW; Ku FC; Chen YT; Chien SH; Yeh CM; Chen TJ; Chiou TJ; Gau JP; Tzeng CH
    Int J Cancer; 2015 Apr; 136(8):1881-7. PubMed ID: 25208807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features?
    Cervantes F; Colomer D; Vives-Corrons JL; Rozman C; Montserrat E
    Leukemia; 1996 Jul; 10(7):1241-3. PubMed ID: 8684009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A
    Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in the incidence of chronic myeloid leukemia.
    Radivoyevitch T; Jankovic GM; Tiu RV; Saunthararajah Y; Jackson RC; Hlatky LR; Gale RP; Sachs RK
    Radiat Environ Biophys; 2014 Mar; 53(1):55-63. PubMed ID: 24337217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 9;22 translocation and bcr rearrangements in chronic myelocytic leukemia patients among atomic bomb survivors.
    Tanaka K; Takechi M; Hong J; Shigeta C; Oguma N; Kamada N; Takimoto Y; Kuramoto A; Dohy H; Kyo T
    J Radiat Res; 1989 Dec; 30(4):352-8. PubMed ID: 2614751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia.
    Hur M; Song EY; Kang SH; Shin DH; Kim JY; Park SS; Cho HI
    Ann Hematol; 2002 Apr; 81(4):219-23. PubMed ID: 11976825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.